NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

CSV download of the complete patent data set.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset the Search Filters to go back to the initial display of all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NHLBI E-223-2002-0-EP-04 FACTORS THAT BIND INTESTINAL TOXINS EP National Stage 03749554.6 Abandoned
NHLBI E-223-2002-0-CA-07 FACTORS THAT BIND INTESTINAL TOXINS CA National Stage 2498225 Abandoned
NHLBI E-223-2002-0-JP-05 FACTORS THAT BIND INTESTINAL TOXINS JP National Stage 2004-536403 Abandoned
NEI E-220-2001-0-SG-22 Nutritional Supplement to Treat Macular Degeneration SG DIV 200403488-0 Expired
NCI E-215-2003-0-US-01 Protocol And Software For Multiplex Real Time PCR Quantification Based On The Different Melting Temperatures Of Amplicons US ORD 10/658,602 Abandoned
NCI E-246-2003-0-US-01 Non Peptide Agonists and Antogonists of Adrenomedullin (AM) And Gastrin Releasing Peptide US 60/500,650 Abandoned
NCI E-276-2005-0-US-01 Novel Small Molecule Inhibitors Of Botulinum Neurotoxin Metalloprotease Activity US 60/501,243 Abandoned
NCI E-275-2002-1-EP-03 Immunotherapy With In Vitro-Selected Antigen-Specific Lymphocytes After Nonmyeloablative Lymphodepleting Chemotherapy EP National Stage 03794636.5 Expired
NCI E-275-2002-1-CA-04 Immunotherapy With In Vitro-Selected Antigen-Specific Lymphocytes After Nonmyeloablative Lymphodepleting Chemotherapy CA National Stage 2497552 Expired
NCI E-035-2002-0-CA-05 Backbone Substituted Bifunctional DOTA Ligands, Complexes and Compositions thereof, and Methods of Using Same CA National Stage 2495442 Abandoned
NCI E-082-2004-2-AU-06 Methods of Preventing or Treating T Cell Malignancies by Adminstering CD2 Antagonists AU National Stage 2003273299 Abandoned
NCI E-275-2002-1-AU-05 Immunotherapy With In Vitro-Selected Antigen-Specific Lymphocytes After Nonmyeloablative Lymphodepleting Chemotherapy AU National Stage 2003265948 Expired
NCI E-035-2002-0-AU-04 Backbone Substituted Bifunctional DOTA Ligands, Complexes and Compositions thereof, and Methods of Using Same AU National Stage 2003270347 Abandoned
NCI E-082-2004-2-PCT-01 Methods of Preventing or Treating T Cell Malignancies by Adminstering CD2 Antagonists PCT PCT COMB PCT/US03/28088 Expired
NCI E-035-2002-0-PCT-02 Backbone Substituted Bifunctional DOTA Ligands, Complexes and Compositions thereof, and Methods of Using Same PCT PCT PCT/US03/27878 Expired
NCI E-275-2002-1-PCT-01 Immunotherapy With In Vitro-Selected Antigen-Specific Lymphocytes After Nonmyeloablative Lymphodepleting Chemotherapy PCT PCT COMB PCT/US2003/027873 Expired
NCI E-082-2004-2-US-02 Methods Of Preventing Or Treating T Cell Malignancies By Adminstering CD2 Antagonists US ORD 10/657,006 Abandoned
NCI E-035-2002-0-EP-06 Backbone-Substituted Bifunctional DOTA Ligands, Complexes and Compositions Thereof, and Methods of Using Same EP National Stage 03752034.3 Abandoned
NCI E-082-2004-2-EP-03 Methods of Preventing or Treating T Cell Malignancies by Adminstering CD2 Antagonists EP National Stage 03755798.0 Abandoned
NCI E-082-2004-2-EP-09 Methods of Preventing or Treating T Cell Malignancies by Adminstering CD2 Antagonists EP DIV 3755798 Abandoned
NCI E-239-2002-0-PCT-02 Minimally Immunogenic Variant of Humanized COL-I Antibody Against Carcinoembryonic Antigen (CEA) PCT PCT PCT/US03/027976 Expired
NCI E-082-2004-2-CN-04 Methods of Preventing or Treating T Cell Malignancies by Adminstering CD2 Antagonists CN National Stage 03824932.4 Abandoned
NCI E-082-2004-2-CA-07 Methods of Preventing or Treating T Cell Malignancies by Adminstering CD2 Antagonists CA National Stage 2497628 Abandoned
NCI E-082-2004-2-JP-05 Methods of Preventing or Treating T Cell Malignancies by Adminstering CD2 Antagonists JP National Stage 2004-534750 Abandoned
NCI E-245-2002-0-FR-09 AKT INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF FR EP 03751981.6 Abandoned
NCI E-245-2002-0-DE-08 AKT INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF DE EP 03751981.6 Abandoned
NCI E-245-2002-0-EP-07 AKT INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF EP National Stage 03751981.6 Abandoned
NCI E-245-2002-0-GB-10 AKT INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF GB EP 03751981.6 Abandoned
NCI E-245-2002-0-CA-05 AKT INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF CA National Stage 2497572 Abandoned
NCI E-245-2002-0-AU-04 AKT INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF AU National Stage 2003270087 Abandoned
NCI E-245-2002-0-PCT-02 AKT INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF PCT PCT PCT/US03/27607 Expired
NCI E-234-2003-0-US-01 Methods For Identifying, Diagnosing, And Predicting Survival of Lymphomas US 60/500,377 Abandoned
NEI E-304-2003-0-PCT-02 Venting and Drying of Samples in Multi-Well Plates PCT PCT PCT/US03/27400 Abandoned
CC E-145-1998-0-US-04 Identification of a Region of the Major Surface Glycoprotein (MSG) Gene of Human Pneumocystis Carinii US DIV 10/654,416 Abandoned
NEI E-304-2003-0-EP-05 Venting and Drying of Smaples in Multi-Well Plates EP National Stage 03749312.9 Abandoned
NEI E-304-2003-0-AU-04 Venting and Drying of Samples in Multi-Well Plates AU National Stage 2003268352 Abandoned
NCI E-323-2003-0-US-01 Minimally Immunogenic Variants of SDR-Grafted Humanized Antibody CC49 and Their Use US 60/498,903 Abandoned
NCI E-282-2000-0-JP-05 Analogs of Thalidomide as Potential Angiogenesis Inhibitors JP National Stage 2002-567927 Abandoned
NIDA E-024-2005-0-US-01 Pyridomorphinans, Pyridazinomorphinans And Use Thereof US 60/497,901 Abandoned
NHLBI E-179-2004-0-US-01 Anti-cancer Vaccines US 60/498,238 Abandoned
NICHD E-225-1997-8-US-01 Methods And Compositions For The Treatment Of Fribrotic Conditions & Impaired Lung Function & To Enchance Lyphocyte Production US CIP 10/647,371 Abandoned
NIAID E-286-2002-1-US-01 The Use Of Aerosolized Capreomycin For The Treatment Of Pulmonary Tuberculosis US 60/497,892 Abandoned
NICHD E-147-1996-5-HK-10 Use of ADNF-For Enhancing Learning and Memory HK EP 03106025.3 Abandoned
NIAID E-115-2001-3-US-02 MVA Expressing Modified HIV Envelope, GAG and POL Genes US ORD 10/646,628 Abandoned
NINDS E-167-2004-0-US-01 Inducing Sterility In Fish By Disrupting The Development Of The GNRH System US 60/497,401 Abandoned
NCI E-187-2000-0-HK-08 A Recombinant Non-Replicating Virus Expressing GM-CSF and Uses Thereof to Enhance Immune Responses HK National Stage 03105975.5 Abandoned
NIAID E-001-2004-0-US-01 Inhibition of HIV-1 Replication by Disruption of the Processing of the Viral Capsid-Spacer Peptide 1 Protein US 60/496,660 Abandoned
NIDCR E-015-2002-1-US-03 Mammalian Sweet Taste Receptors US CON 10/645,441 7507793 Expired PDF
NCI E-009-2000-0-HK-24 Anti-EGFRvIII scFvs With Improved Cytotoxicity and Yield, Immunotoxin Based Thereon, and Methods of Use Thereof HK National Stage 03105948.9 Abandoned
NCI E-148-1998-1-US-04 Molecular Clones With Mutated HIV GAG/POL,SIV GAG And SIV ENV Genes US DIV 10/644,027 7608422 Abandoned PDF